Tg Therapeutics Inc share price logo

Tg Therapeutics Inc Share Price

NASDAQ: TGTX

Mid Cap

$31.52

-0.23

(-0.72%)

as on

Tg Therapeutics Inc Stock Performance

as on March 31, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $31.32
    $32.13
    downward going graph

    0.63%

    Downside

    1.94%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $25.28
    $46.48
    downward going graph

    19.80%

    Downside

    47.46%

    Upside

    downward going graph

Tg Therapeutics Inc share price movements today

Previous Close
$31.75
Open
$31.80
Volume
1.3M
Day's Low - High
$31.32 - $32.13
52 Week Low - High
$25.28 - $46.48

Tg Therapeutics Inc Historical Returns

1 Month Return
+ 9.11 %
3 Month Return
+ 5.7 %
1 Year Return
-20.09 %
3 Year Return
+ 109.51 %
5 Year Return
-34.63 %

Tg Therapeutics Inc Stock Fundamentals & Key Indicators

Check Tg Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$5.1B

EPS (TTM)

1.2432

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

-0.06%

PE Ratio (TTM)

11.46

Industry PE ratio

7.887522123893805

PEG Ratio

1.6144

EBITDA

123.4M

Revenue (TTM)

616.3M

Profit Margin

72.56%

Return On Equity TTM

102.75%

Tg Therapeutics Inc Stock Valuation

Track how Tg Therapeutics Inc P/E has moved over time to understand its valuation trends.

Tg Therapeutics Inc in the last 5 years

  • Overview

  • Trends

Lowest (-198.55x)

September 30, 2024

Industry (7.89x)

March 31, 2026

Today (11.46x)

March 31, 2026

Highest (140.20x)

March 31, 2025

LowHigh

Today’s Price to Earnings Ratio: 11.46x

Tg Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Tg Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Tg Therapeutics Inc image
Tg Therapeutics Inc
BUY$5.1B-34.63%11.4672.56%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$42.1B123.88%136.798.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$110.0B106.23%28.2532.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$32.5BNA115.055.37%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$78.0B58.37%17.7931.41%

Stock Returns calculator for Tg Therapeutics Inc Stock including INR - Dollar returns

The Tg Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Tg Therapeutics Inc investment value today

Current value as on today

₹88,584

Returns

-₹11,416

(-11.42%)

Returns from Tg Therapeutics Inc Stock

-₹20,061 (-20.06%)

Dollar Impact

₹8,645 (+8.64%)

Analyst Recommendation on Tg Therapeutics Inc Stock

Based on 15 analysts

BUY

80.00%

Buy

13.33%

Hold

6.67%

Sell

Based on 15 analysts, 80% of analysts recommend a 'BUY' rating for Tg Therapeutics Inc. Average target price of $44.43

Tg Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Tg Therapeutics Inc.

What analysts predicted

29.06%UPSIDE

Target Price

$44.43

Current Price

$31.52

Analyzed by

15 Analysts

Target

$44.43

Tg Therapeutics Inc target price $44.43, a slight upside of 29.06% compared to current price of $31.52. According to 15 analysts rating.

Tg Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for Tg Therapeutics Inc Stock has decreased by -9% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-9% versus previous 30 day period

Tg Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
165
43
63
73
83
108
120
141
161
192
Gross Profit
162
36
57
65
74
92
105
122
133
154
Operating Income
114
-12
-9
8
12
29
8
34
29
50
EBITDA
117
-11
-8
10
15
32
12
37
32
51
Interest Expense
3
2
2
3
10
7
6
6
6
6
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
113
-14
-10
6
4
25
5
30
25
45
Income Tax Expense
0
0
0
0
0
2
0
2
-364
22
Net Income
113
-14
-10
6
3
23
5
28
390
23
Net Profit Margin
68.71%
-32.79%
-16.87%
9.36%
4.63%
21.57%
4.19%
19.97%
241.73%
11.96%

Tg Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
0
0
0
0
0
6
2
233
329
616
Gross Profit
0
0
0
0
0
5
2
219
290
515
Operating Income
-78
-118
-174
-169
-273
-344
-218
20
41
123
EBITDA
-78
-118
-173
-167
-272
-341
-213
26
49
134
Interest Expense
-
1
1
5
6
5
10
12
24
26
Depreciation
-
0
0
0
0
0
0
0
0
0
Income Before Tax
-78
-118
-173
-172
-279
-348
-223
13
25
107
Income Tax Expense
0
0
0
6
6
7
5
0
2
-339
Net Income
-78
-118
-173
-172
-279
-348
-223
12
23
447
Net Profit Margin
-51353.45%
-77749.86%
-114132.89%
-113730.92%
-183803.29%
-5204.08%
-8036.34%
5.42%
7.11%
72.56%

Tg Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-14
-10
6
3
23
5
28
390
23
Operating Cash Flow
-13
-8
5
-12
-25
-28
7
-23
19
Investing Cash Flow
-44
-9
1
-9
15
-12
-3
46
-15
Financing Cash Flow
0
0
0
134
-6
-6
-6
-78
1
Change in Cash
-57
-17
7
112
-15
-47
-2
-55
5

Tg Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-118
-173
-172
-279
-348
-198
12
23
447
Operating Cash Flow
-93
-128
-132
-214
-295
-176
-31
-40
-24
Investing Cash Flow
-8
1
0
-24
0
-20
-50
-1
13
Financing Cash Flow
133
113
204
679
41
0
72
128
-89
Change in Cash
31
-14
70
440
-254
-196
-9
86
-100

Global Institutional Holdings in Tg Therapeutics Inc

Funds
Holdings
Susquehanna International Group, LLP
0.76%
Geode Capital Management, LLC
2.13%
Pictet Asset Manangement SA
0.91%
Morgan Stanley - Brokerage Accounts
0.78%
T. Rowe Price Associates, Inc.
0.6%
See all

Tg Therapeutics Inc News & Key Events

  • img

    Today's Timeline - 14 January

    Wed, 08:22 PM

    -

    TG Therapeutics reports preliminary 2025 revenue of $616 million, shares rise 11.6% to $31.10.

Insights on Tg Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 9 quarters, 43.97M → 192.57M (in $), with an average increase of 16.6% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, TGTX stock has moved up by 4.3%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Insmed Incorporated has given 799.2% return, outperforming this stock by 689.7%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Insmed Incorporated has given 101.0% return, outperforming this stock by 121.1%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 390.89M → 23.03M (in $), with an average decrease of 94.1% per quarter

About Tg Therapeutics Inc

tg therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. currently, the company is developing two therapies targeting hematological malignancies. tg-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the cd20 antigen found on mature b-lymphocytes. tg therapeutics is also developing tgr-1202, an orally available pi3k delta inhibitor. the delta isoform of pi3k is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of b-lymphocytes. both tg-1101 and tgr-1202 are in clinical development for patients with hematologic malignancies. the company also has pre-clinical programs to develop irak4 inhibitors, and anti-pd-l1 and anti-gitr antibodies. tg therapeutics is headquartered in new york city and is traded on nasdaq under the ticker symbol "tgtx".
OrganisationTg Therapeutics Inc
Headquarters3020 Carrington Mill Blvd., Morrisville, NC, United States, 27560
IndustryHealth Technology
CEOMr. Michael S. Weiss Esq., J.D.
E-voting on sharesClick here to vote

Key Management of Tg Therapeutics Inc

Name

Title

Mr. Michael S. Weiss Esq., J.D.

Chairman, CEO & President

Mr. Sean A. Power CPA

CFO, Corporate Secretary & Treasurer

Ms. Jenna Bosco

Senior Vice President of Corporate Communications

Mr. Adam Waldman

Chief Commercialization Officer

FAQs

What is Tg Therapeutics Inc share price today?

Tg Therapeutics Inc share price today is $31.52 as on at the close of the market. Tg Therapeutics Inc share today touched a day high of $32.13 and a low of $31.32.

What is the 52 week high and 52 week low for Tg Therapeutics Inc share?

Tg Therapeutics Inc share touched a 52 week high of $46.48 on and a 52 week low of $25.28 on . Tg Therapeutics Inc stock price today i.e. is closed at $31.52,which is 32.19% down from its 52 week high and 24.68% up from its 52 week low.

What is Tg Therapeutics Inc's market capitalisation today?

Tg Therapeutics Inc market capitalisation is $0.01T as on .

How to invest in Tg Therapeutics Inc Stock (TGTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Tg Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Tg Therapeutics Inc Shares that will get you 0.0476 shares as per Tg Therapeutics Inc share price of $31.52 per share as on March 31, 2026 at 1:29 am IST.

What is the minimum amount required to buy Tg Therapeutics Inc Stock (TGTX) from India?

Indian investors can start investing in Tg Therapeutics Inc (TGTX) shares with as little as ₹94.702 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹947.02 in Tg Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Tg Therapeutics Inc share’s latest price of $31.52 as on March 31, 2026 at 1:29 am IST, you will get 0.3173 shares of Tg Therapeutics Inc. Learn more about fractional shares .

What are the returns that Tg Therapeutics Inc has given to Indian investors in the last 5 years?

Tg Therapeutics Inc stock has given -34.63% share price returns and 29.05% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?